glp-1 hims The legal battle is heating up. Novo Nordisk sued & Hers after the telehealth company announced plans to sell a compounded oral GLP-1 pill positioned as a lower-cost alternative to Hims' Pivot to Branded Obesity
Description
A required warning about the risk, which it classifies as very rare, affecting about 1 in 10,000 users, will appear on product labels for Ozempic and Wegovy
Our choice of GRAS-status bacterial strains ensures that Fleur maintains an excellent safety profile
The comparison is most relevant and most favorable to Direct Meds for the cash-pay patient segment that represents the majority of GLP-1 seekers in the current market
Our scientific team at Emery Pharma specializes in this type of analysis
UTIs did not emerge as a statistically significant side effect in any of these trials
Initiate a Chargeback Sue your bank if refund requests are ignored
